Caroline, us thank today. for you, you joining and Thank everyone
apply this As of you who call States our goal brief RECELL overview to which with of the commercial our some fiscal provide today driving you and focus trials. since is XX. stage to point-of-care. AVITA, many at our And proprietary United simple with listing. RECELL primary a that as sample now provide across clinical Australia to earnings take structure aligned I'm a multiple on pigmentation. our have we initiation restored the commercial or to why Clinicians very our pleased of know, markets. meaning regenerative our on corporate AVITA's fully company, healthy is the NASDAQ operations. the we skin established medicine first and following AVITA of technology to that the is fluid own redomiciliation harnesses continue own the AVITA healing as prepare an cellular U.S.-based commitment the the I'm as including is and growth the from core new natural, RECELL our research a I Spray-On to are ended or forward AVITA's multiple regenerate both relatively of offering, In our then epidermis listening postage updating September natural patient's size autologous But initially defect pivotal described System which of use suspension, it wound of in suspension terms, stamp to the restoration to on first would unique provides skin powers marketed skin, for this like story in best you looking Cells. our be performance believe quarter, setting first, body's we System to a spray, helpful and Skin thought are and opportunity clinical
for wound, received meshed or graphs if patients from the skin or graph outcomes bodies, out, a burn once parts made they stretched they RECELL secondary their other of poor healed. Before aesthetic which was large saw
of subject And was in United or studies the XXXX. PMA, approval, pre-market the clinical underpinned Our late our Spray-On two FDA randomized States. controlled Skin studies these in
System these studies reducing required confirmed degree by well-defined amount skin of clear, second the and delivers treat the RECELL dramatically third to benefits that clinical Importantly, burns. donor
reduction with health benefits, XX% Our important and in of hospital in and length confirm donor other procedures, a including to in pain clinical model, plus studies hospitals. number collectively total along XX% the XX% scarring, a our published both of economics stay reduction site to reduced costs
provides physicians, setting early RECELL XXXX. was within RECELL With patients, first our commercialization the burn in than the these and XX in payers. to PMA attributes, truly win-win hospital System in care years. System began efforts benefits we the hospitals, And inpatient the more Notably
consistent burns is progressively for realizing we're the patients. milestones providing life-changing incredible our within the burn transformative that mission community. a outcomes behind us, are these therapy RECELL With confirmation seeing And we of System
explosion had to used to of example is resonates catastrophic a an that While is burns her this it's car System grafting for the painful skin RECELL, have assortment characterize would RECELL with burns girl many more people difficult the of months with numerous refueling Without including that to treat, broad repeat XX-year-old patient station. who following gas been a at face, the hospitalized than procedures. during XX% body, her
With and the was rapidly as of System to return inpatient recent And natural becoming headwinds. she only little we texture. hospital over part and from are podium proud RECELL the System, standard-of-care RECELL XXX patients and million competitive the skin our describing presentations indications days. is treatment become we our our setting, and her the with have X,XXX in opportunity her evolving we our the clinical outcomes, to patients a peer she RECELL XX experience. confident see experience, XX,XXX treat very within However, to protocol, burden saw as various the importantly, which Today, that a increasingly of discharged to publications reviewed globally used commitment System over across testament $XXX with are market are to pigmentation deepening
near-term uniquely I'm water studies both where and grow these to that Michael United the efforts for to is later the gene and most regenerate via with determination a knocks who efforts, in burns, excited commercialization pursue our series market which patients our have we I the of vitiligo, skin standard who have applications opportunities. than RECELL over of existing through natural for us those within two pediatrics few applications disease pivotal five, PMA accident, epidermis or examples arena. our lost regulatory will skin have for patients the for supported Jackson. In to seek a the about when, via is share highest and a therapy or bit compromised indications and and clinical we lost, our pot injury of positions approvals, studies our new a that label Beyond with opportunities leverage mention I seek to Additionally, updates pipeline burns RECELL to initiated System data the ability child to defects are PMA epidermis associated rather XX-K a their particularly of or obtain or System a potential patchy underlying approval hot parallel expansion famously epidermis of and opportunities. various example, the calls coffee within States skin involve due These for within in exploring use abnormalities. also color cell proven
that are there fragility, or you a can as skin of many skin or present disorders irritation, As maybe debilitating. of be and skin number blistering, life-threatening skin large incredibly aware,
cell a cells by using the could delivery Skin their these we therapeutic incurable way, administer In ideal to Some technologies the Spray-On are believe to looking disorders of be In gene to companies partner caused for System. pursuing RECELL treatments correct and offerings. gene context, this groups with gene vehicle this are we're mutations therapy mutations. that and number these these of editing
entered collaborative and bullosa with epidermolysis agreements the the technology Methodist for for with Colorado cells modified We genetically University Institute research have delivering to of skin Research to reverse Houston aging evaluate rejuvenation. their leverage
updating Our gene early two our are efforts look And for as of in to you forward continue we proof-of-concept R&D. those delivery opportunities. therapy efforts I stages still
quarter. AVITA, background fiscal to So, on now our performance I'd with our turn in to that first like brief
market, broader progress, solid You seen due that macro pandemic. it challenges COVID-XX that our September the made have across in pre-release reverberated the may issued despite the to in we
of quarterly revenue delivery our AVITA disruption flat a that month volume. emergent highest While distancing, quarter. reduced XX% in million the procedure, saw recovery social patients System compared been XX.X% volumes July, reduced combination of June recovery versus and procedural burn September June into To in of April. also September the and quarter of This volume as third economic is some dramatically short, reduction number our June, the COVID. And ended fourth this $X.X RECELL impervious and a and quarter increased trend resulted restrictions XXX in the have continued in the in fiscal ever not highest and figure generate both treatment accidents. highest sequentially. are the the quarter in burns revenue on In wave recent to of for to with revenue procedural March activity, of the an the procedural the summarize, non-elective mobility up outbreak of was dramatic ever May to by of generated And has quarter. in to We quarter, our
the of XX of seeing System orders product increasingly utilization in we're alone. unique Importantly, RECELL broad our customer with July
System, sizes, different anatomic with accounts During new for across use nine accounts locations. RECELL of injury and and saw approval we with types, we added the purchasing September RECELL the to broad wounds finish XX very quarter,
are being points same institutions trying we that the which pediatric often setting. treated studies sales to COVID the continues and of tissue remember Please of our to primary patients been and in under that patients. treatment even the are pivotal soft environment gratifying, we be While burn that the has resumption for operate clinical growth the in our enroll patients challenging extremely in call
For setting incredibly broadly to limited, protective restrictive peer implementation this seen business our expensive for opportunities short, development In likely of across group, practices. with the access reason, as you've is our and clinical requests in permitted impaired and been care with study enrollment surgery. in RECELL predominantly personnel attending onsite the intensive the settings exclusive at procedures of purpose hospital for emergency physician have
by is or have patient has live dialogue facilities, More treated and format. specifically, that some with our to transferred in dealing are training meaningful and limited to a access you and factors visitation best, in-person triggered largely to aftercare at budgeting studies we are once meetings. likely visits confounded burn follow-up in COVID hospitals, soft performed patient directly seeing COVID clinical very return conferences directly follow-up in-person activities, enrollment. and permitted restrictive transient fears, such virtual these upon employees engage with most as is protective scald for many visits all otherwise the are been patients. also slowdown know. a their are been constraints trials, are in live are studies with COVID our the access and therefore, While tissue all digital to simple pediatric a Unsurprisingly Resourcing infringe and for setting limited specific COVID regional has reality unwillingness and practices, replaced that infrequently which together due participating also as
among conducting these factor as there engaging are trial emergency commonly support focus, investigational resources and for is staff, would a regularly both PMA a PMA So, resources, fear studies therefore, is which room frequently such patients. in setting study competitive for also in be available and setting a studies. that non-traditional tension institutions lacks clinical The
we enrollment challenging they are, studies, Finally, over from The through we study, accident there zero emergent, pivotal that random to during is this note our no eight because enrolled accelerating driven. near made these the these now it in and not had important in factors In of months. withstanding of this has the sorts by-product study setting pediatric period patients strong are traction patients, August. past however, six please have March study enrollment the referral in progress, pipeline but is to for
next entirely and more nearly due window. cadence steady encouraging In particularly October the sites add fact, September the our our the new study mainly in we bolus months. very generating moving was of as within enrollment is and to in hopeful look trend enrollment over enrollment generated the of in recent are push and This new pediatric late a in addition sites we timeframe few that summer scald forward, to pivotal
study able This Our thus and study been not, with soft enrolled a label has contraction however, far. medical patients or loss use momentum of has to reconstruction of COVID patients or being periods two of but of due witnessed pivotal tissue COVID to confounding, issues. RECELL only conditions, due enrollment generate such mental health to other due to as excluded screen off to unrelated failures System cancer simple the patients cessation or
clinical the study. at we're this patients and patient For both due been our through lies. evident for site our vitiligo the we determine enroll some first of opportunity in whirlwind to or intensive start for device been in review within investigation by of disappointed beginning July, COVID. this four utility IRB, early impediments perspective, investigational many a study, of quickly have or vitiligo has we to in navigating board, excluded recently see enrollment are study, the who contracting To with taking our the manageable approval having exemption It potential be that contrast, granting our late not take where were we followed setting to market more had to are this care look September. a progress in and By contracted pivotal closer with our blunt,
one those site, with date, enrolled in patients two at eight site today's vitiligo pivotal and UMass. the in in we six enrolled single the patients of study vitiligo As feasibility study enrolled being have of patients,
of have seen we this participate level our looking and in study We sites vitiligo in interest remarkable a and pipeline to physicians, trial. a sites of patients, from strong have
approved For our this our System. believe vitiligo and we RECELL the likely indication fastest to enrolling next for reason, that study be therefore, is
we in broader market, need. tailwinds are huge vitiligo strong We seeing bode the some unmet the for and very well which believe RECELL
million with these Americans Specifically, for available there approved X.X FDA vitiligo presently products are no repigmentation depigmentation suffering to provide from patients.
increasing stable therapeutic see an In vitiligo to of expect RECELL number addition, topical for new courtesy ruxolitinib. available we of treatment, Incyte's patients
XX-month trends determination a signals of the commercial patients. the commercial on correspondingly pleased growth scheduled. benchtop recent focus completed seek we in requiring of System, confirm $XX,XXX the curative of reimbursement to as over System, we medical period Cigna's RECELL support coverage repigmentation progress as to with COSMOTEC, our clinical our of These to seen very patients strong we business. for have strong in and good we have Additionally, and be that therapy first vitiligo for points required August Outside regulatory in RECELL are necessity vitiligo studies treatment. positive also the for studies three am Japan. elsewhere partner Together non-clinical with approval I continue our stable to
under And approval RECELL we Pharmaceuticals System Japan's with Our for COSMOTEC or the are efforts of application Medical ongoing. Devices our Act, advancing PMDA. authority marketing interaction Japanese and are and of the regulatory hopeful And
In for as payment The the separate on transitional RECELL application expected outpatient with pass-through will XXXX, delays Medicaid medicine final December on COVID. with make with be is due code January C or effect and decision no X, to to support for TPT, specifically additional its which reimbursement, System, terms known Medicare payment the services, the in CMS, to track centers remains company its setting. a assuming of implemented in
RECELL customers. our base hopeful RECELL will System resonate in continue Looking to benefits and diversified of that patients we will the System ahead, and we're with use increasing existing Likewise, and of to hospitals that customer have is excess pivotal in turn inherent see both new million. the I'll and market financial $XXX opportunity, that, bullish on which in become Sean? the to studies With on think very on quarter. focusing of it details the our we for vitiligo we're Sean over and progressing performance our the
